Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342226 | 0.82 | POLB (0.73) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL2112295 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL6748039 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL1046239 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL1268829 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL1948477 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL2705461 | 0.79 | L3MBTL1 (0.83) | USP2POLBALDH1A1GAAMEN1 | |
| SCHEMBL2706987 | 0.79 | USP2 (0.76) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL436674 | 0.79 | PKM (0.89) | USP2POLBALDH1A1GAAPKM | |
| SCHEMBL3236916 | 0.79 | MAPT (0.80) | USP2POLBALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | USP2 3178/4885POLB 4039/4885ALDH1A1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.